1. Home
  2. HCWB vs HTCR Comparison

HCWB vs HTCR Comparison

Compare HCWB & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCWB
  • HTCR
  • Stock Information
  • Founded
  • HCWB 2018
  • HTCR 2009
  • Country
  • HCWB United States
  • HTCR Japan
  • Employees
  • HCWB N/A
  • HTCR N/A
  • Industry
  • HCWB Biotechnology: Pharmaceutical Preparations
  • HTCR EDP Services
  • Sector
  • HCWB Health Care
  • HTCR Technology
  • Exchange
  • HCWB Nasdaq
  • HTCR Nasdaq
  • Market Cap
  • HCWB 10.8M
  • HTCR 11.6M
  • IPO Year
  • HCWB 2021
  • HTCR 2022
  • Fundamental
  • Price
  • HCWB $3.60
  • HTCR $0.54
  • Analyst Decision
  • HCWB Strong Buy
  • HTCR
  • Analyst Count
  • HCWB 1
  • HTCR 0
  • Target Price
  • HCWB $35.00
  • HTCR N/A
  • AVG Volume (30 Days)
  • HCWB 28.1K
  • HTCR 90.4K
  • Earning Date
  • HCWB 08-18-2025
  • HTCR 08-13-2025
  • Dividend Yield
  • HCWB N/A
  • HTCR 3.77%
  • EPS Growth
  • HCWB N/A
  • HTCR N/A
  • EPS
  • HCWB N/A
  • HTCR N/A
  • Revenue
  • HCWB $832,841.00
  • HTCR $29,625,381.00
  • Revenue This Year
  • HCWB $178.36
  • HTCR N/A
  • Revenue Next Year
  • HCWB N/A
  • HTCR $8.59
  • P/E Ratio
  • HCWB N/A
  • HTCR N/A
  • Revenue Growth
  • HCWB N/A
  • HTCR 72.95
  • 52 Week Low
  • HCWB $3.51
  • HTCR $0.39
  • 52 Week High
  • HCWB $100.80
  • HTCR $3.38
  • Technical
  • Relative Strength Index (RSI)
  • HCWB 32.23
  • HTCR 63.52
  • Support Level
  • HCWB $3.51
  • HTCR $0.45
  • Resistance Level
  • HCWB $4.65
  • HTCR $0.58
  • Average True Range (ATR)
  • HCWB 0.32
  • HTCR 0.04
  • MACD
  • HCWB -0.03
  • HTCR 0.01
  • Stochastic Oscillator
  • HCWB 21.05
  • HTCR 73.27

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

Share on Social Networks: